Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 327-332

  Raboud, Janet M ^a,b,h   Abdurrahman, Zainab B ^c   Major, Carol ^d   Millson, Peggy ^b   Robinson, Greg ^g   Rachlis, Anita ^b,e   Bayoumi, Ahmed M ^b,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d ONTARIO HIV TREATMENT NETWORK   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h Prosserman Center for Health Research   (Canada)

Author keywords

Access to health care; HIV; Viral load measurement

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CANADA; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; ONTARIO; TIME FACTORS; VIREMIA;

EID: 21544433249     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000143603.94728.b2     Document Type: Article

References (22)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. July 14, 2003. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/ archive/PDA_AA_071403.pdf. Accessed September 22, 2004.
2. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS. 1996;3:S1-S11.
3. Holodniy M. Viral load monitoring in HIV infection. Curr Infect Dis Rep. 1999;1:497-503.
4. Mylonakis E, Paliou M, Rich JD. Plasma viral load testing in the management of HIV infection. Am Fam Physician. 2001;63:483-490, 495-496.
5. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:2936-2937.
6. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
7. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and implications for survival. Arch Intern Med. 2000;160:3114-3120.
8. McKinney MM, Marconi KM. Delivering HIV services to vulnerable populations: a review of CARE Act-funded research. Public Health Rep. 2002;117:99-113.
9. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35:389-412.
10. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
11. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res. 1999;34:123-144.
12. Forte T, Bayoumi AM, Remis RS, et al. Representativeness of the HIV Ontario Observational Database (HOOD). Paper presented at: Twelfth Annual Canadian Conference on HIV/AIDS Research; April 10-13, 2003; Halifax, Nova Scotia. Abstract 337.
13. Liang K-Y, Zeger SL. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
14. Laine C, Zhang D, Hauck WW, et al. HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:270-274.
15. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J Epidemiol Community Health. 1999;53:4-8.
16. Strathdee SA, Palepu A, Cornelisse P, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
17. Loughlin A, Metsch L, Gardner L, et al. Provider barriers to prescribing HAART to medically-eligible HIV infected drug users. AIDS Care. 2004; 16:485-500.
18. Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med. 2003;4:33-37.
19. Clarke SM, Mulcahy FM. Antiretroviral therapy for drug users. Int J STD AIDS. 2000;11:627-631.
20. Weber AE, Yip B, O'Shaughnessy MV, et al. Determinants of hospital admission among HIV positive people in British Columbia. CMAJ. 2000; 162:783-786.
21. Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21:187-210.
22. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: a comparison of Canadian and Western European jurisdictions over time. CMAJ. 2000;162:1709-1713.